Targeted Therapies With no Compromise
RS Research is a clinical-stage biotechnology start-up discovering and developing smart nanomedicines for targeted therapy.
Superior Therapeutic Index
Sagitta® Bir and Sagitta® Dui are discovered to address this challenge with biodegradable conjugation platforms that reinforce ideal performances in terms of the therapeutic index, PK and manufacturability.
Targeted Therapies With no Compromise
RS Research is a clinical-stage biotechnology start-up discovering and developing smart nanomedicines for targeted therapy.
SUPERIOR THERAPEUTIC INDEX
Sagitta® Bir and Sagitta® Dui are discovered to address this challenge with biodegradable conjugation platforms that reinforce ideal performances in terms of the therapeutic index, PK and manufacturability.RS Research announces poster presentation at the ESMO 2022 Congress
RS Research, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted chemotherapy, announced the acceptance of a poster presentation on Phase Ia/Ib study of RS-0139 at the European Society for Medical Oncology (ESMO) 2022 Congress on 9-13 September 2022 in Paris – France.
RS Research announces dose escalation in the Phase I clinical study of RS-0139
Designing drug candidates with improved safety profile and superior therapeutic index based on its proprietary Sagitta® drug delivery technology, RS Research will advance to the next dose level following the positive review of the safety data by the IDMC.
Building better docetaxel therapy with nanocarrier technology, covered by BioWorld
RS-0139, the lead candidate of Sagitta® which targets a docetaxel payload to tumors expressing the integrin receptor, has passed the first test of its novel nanocarrier technology, getting approval to move up from the initial dose in the phase I trial.
